Inseego Appoints Steve Harmon as Chief Revenue Officer, Stock Surges
Inseego, a global leader in 5G and IoT solutions, announced yesterday the appointment of Steve Harmon as Chief Revenue Officer, a role newly created within
Home
Page 339
Galera Therapeutics’ Stock Dips on FDA’s Phase 3 Trial Directive
Galera Therapeutics, a leading biopharmaceutical company, recently disclosed receiving official meeting minutes from a Type A meeting with the Food and Drug Administration (FDA) held
GeneDx Q3 Results: 40% YoY Growth, $53M in Revenue, Stock Continues Decline
GeneDx Holdings Corp, a leading provider of enhanced health insights through genomic and clinical expertise, unveiled its revenue results for the third quarter (Q3) of
Avenue Therapeutics Announces Pricing of Public Offering, Faces Stock Decline
Avenue Therapeutics, a prominent specialty pharmaceutical company with a primary focus on advancing therapies for neurologic diseases, revealed today the pricing details of its public
Global Leaders Converge in Washington for International Counter Ransomware Summit
Just a day after the Biden administration introduced a comprehensive executive order on artificial intelligence, the White House is now hosting leaders from around the
US Treasury Prepares for Quarterly Refunding Update; Market Anticipates Impact on Bond Supply
On Monday, the US Treasury announced its preparations for a quarterly refunding update scheduled for Wednesday. This pivotal update is set to unveil the extent
Sientra Reports Q3 Revenue Below Estimates; Stock Value Declines
Sientra, a leading Irvine-based manufacturer specializing in implants and related products for breast augmentation and reconstruction surgery, witnessed a decline in its stock value following
Kintara Therapeutics Faces Stock Dip After Disappointing VAL-083 Study Results
In a significant development, Kintara Therapeutics, a prominent biopharmaceutical entity specializing in the advancement of novel solid tumor cancer treatments, witnessed a dip in its
Cardio Diagnostics Secures Innovation Technology Contract with Vizient
Cardio Diagnostics Holdings, a trailblazer in artificial intelligence-powered precision cardiovascular medicine tests, has announced the acquisition of an Innovation Technology contract from Vizient, the nation’s
Avalo Therapeutics Completes Divestiture of 800 Series Assets to AUG Therapeutics
Avalo Therapeutics, a pioneering biotechnology company dedicated to the development of innovative treatments for immunological diseases, announced today the successful completion of the divestiture of
